The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells
Open accessAbstract
Elevated expression of mammalian polo-like kinase (Plk)1 occurs in many different types of cancers, and Plk1 has been proposed as a novel diagnostic marker for several tumors. We used the recently developed vector-based small interfering RNA technique to specifically deplete Plk1 in cancer cells. We found that Plk1 depletion dramatically inhibited cell proliferation, decreased viability, and resulted in cell-cycle arrest with 4 N DNA content. The formation of dumbbell-like chromatin structure suggests the inability of these cells to completely separate the sister chromatids at the onset of anaphase. Plk1 depletion induced apoptosis, as indicated by the appearance of subgenomic DNA in fluorescence-activated cell-sorter (FACS) profiles, the activation of caspase 3, and the formation of fragmented nuclei. Plk1-depletion-induced apoptosis was partially reversed by cotransfection of nondegradable mouse Plk1 constructs. In addition, the p53 pathway was shown to be involved in Plk1-depletion-induced apoptosis. DNA damage occurred in Plk1-depleted cells and inhibition of ATM strongly potentiated the lethality of Plk1 depletion. Although p53 is stabilized in Plk1-depleted cells, DNA damage also occurs in p53 −/− cells. These data support the notion that disruption of Plk1 function could be an important application in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139
Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S., & Bonner, W. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.10.5858 · Cited by 5,438
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage
Paull, T. T., Rogakou, E. P., Yamazaki, V., Kirchgessner, C. U., Gellert, M., & Bonner, W. M. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00610-2 · Cited by 2,098
Death and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
A novel form of Epstein-Barr virus latency in normal B cells in vivo
Miyashita, E. M., Yang, B., Lam, K. M. C., Crawford, D. H., & Thorley-Lawson, D. A. (1995) · Cell · doi:10.1016/0092-8674(95)90513-8 · Cited by 1,593
A DNA vector-based RNAi technology to suppress gene expression in mammalian cells
Sui, G., Soohoo, C., Affar, E. B., Gay, F., Shi, Y., Forrester, W. C., & Shi, Y. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082117599 · Cited by 1,104
(1999) · PubMed · Cited by 1,030
Schultz, L. B., Chehab, N. H., Malikzay, A., & Halazonetis, T. D. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.151.7.1381 · Cited by 904
Rogakou, E. P., Nieves-Neira, W., Boon, C., Pommier, Y., & Bonner, W. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.13.9390 · Cited by 708
(1998) · PubMed · Cited by 525
Polo-like kinases: a team that plays throughout mitosis
Glover, D. M., Hagan, I. M., & Tavares, Á. A. M. (1998) · Genes & Development · doi:10.1101/gad.12.24.3777 · Cited by 424
Alexandru, G., Uhlmann, F., Mechtler, K., Poupart, M.-A., & Nasmyth, K. (2001) · Cell · doi:10.1016/s0092-8674(01)00362-2 · Cited by 353
Polo-like kinases: positive regulators of cell division from start to finish
Nigg, E. A. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80121-x · Cited by 344
Spankuch-Schmitt, B., Bereiter-Hahn, J., Kaufmann, M., & Strebhardt, K. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.24.1863 · Cited by 327
Caffeine inhibits the checkpoint kinase ATM
Blasina, A., Price, B. D., Turenne, G. A., & McGowan, C. H. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80486-2 · Cited by 295
Smith, M. R., Wilson, M. L., Hamanaka, R., Chase, D., Kung, H.-F., Longo, D. L., & Ferris, D. K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6633 · Cited by 248
Knecht, R., Elez, R., Oechler, M., Solbach, C., von Ilberg, C., & Strebhardt, K. (1999) · PubMed · Cited by 232
Cited by
Cell death by mitotic catastrophe: a molecular definition
Castedo, M., Perfettini, J.-L., Roumier, T., Andreau, K., Medema, R., & Kroemer, G. (2004) · Oncogene · doi:10.1038/sj.onc.1207528 · Cited by 1,269
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
Targeting polo-like kinase 1 for cancer therapy
Strebhardt, K., & Ullrich, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1841 · Cited by 841
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krššák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., et al. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.037 · Cited by 834
Rogers, C., Erkes, D. A., Nardone, A., Aplin, A. E., Fernandes-Alnemri, T., & Alnemri, E. S. (2019) · Nature Communications · doi:10.1038/s41467-019-09397-2 · Cited by 826
Metadata
- Authors
- Liu, X., & Erikson, R. L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-05-05
- Volume
- 100
- Issue
- 10
- Pages
- 5789-5794
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2020411912
- Cited by
- 472
- References
- 17
- FWCI
- 7.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.